Stories

Harm reduction efforts in the Middle East and Africa face distinct challenges shaped by restrictive regulation, limited public awareness, and uneven access to safer nicotine alternatives. Advocates argue that in regions where smoking rates remain high, excluding tobacco harm reduction from public health strategies may slow progress in reducing smoking-related disease and mortality. The discussion highlights the importance of local evidence, consumer voices, and culturally relevant risk communication in shaping more effective nicotine policy. It also raises broader questions about whether global tobacco control frameworks adequately reflect the needs and realities of countries outside Europe and North America.

"The Household Case for Innovation" survey by We Are Innovation interviews friends and family of ex-smokers in five countries, highlighting positive impacts of Innovative Nicotine Products (INPs) on cessation. Results show reduced secondhand smoke exposure and improved social interactions and health habits post-quitting, with strong support for INP access. Findings emphasize the influence of witnessing successful INP use on perceptions and advocate for including broader perspectives in tobacco control debates. Support for INP access correlates with personal experiences, challenging policymakers to consider a wider range of stakeholders. Experience-driven advocacy underscores the importance of involving affected communities in shaping tobacco control policies.

Warnings from tobacco harm reduction advocates in the Asia-Pacific region are intensifying as several Southeast Asian countries consider stricter nicotine regulation modelled on Australia’s approach. Critics argue that highly restrictive policies on vaping and other reduced-risk nicotine products have contributed to expanding illicit markets while doing little to eliminate demand for nicotine among adult consumers. Researchers and public health commentators continue to debate whether prohibition-focused regulation may unintentionally reinforce cigarette smoking by limiting access to lower-risk alternatives. The discussion reflects broader international concerns about how governments can balance youth protection, enforcement, consumer behaviour, and evidence-based harm reduction strategies in nicotine policy.

Australia’s increasingly restrictive approach to smoking and nicotine regulation continues to fuel debate over the unintended consequences of prohibition-focused public health policy. Critics argue that limiting access to lower-risk nicotine alternatives while maintaining high tobacco taxes has contributed to the rapid growth of illicit cigarette markets across the country. Researchers and harm reduction advocates continue to warn that policies focused primarily on reducing nicotine use overall may overlook the behavioural realities of addiction and consumer demand. The debate reflects broader international tensions between harm minimisation, public health objectives, taxation policy, and evidence-based approaches to reducing smoking-related disease and mortality.

Growing divisions within the global nicotine debate are becoming increasingly visible through competing public health narratives surrounding World Vape Day and World No Tobacco Day. While both movements ultimately focus on reducing smoking-related disease and mortality, major disagreements remain over the role of vaping and other reduced-risk nicotine products in achieving that goal. Harm reduction advocates argue that non-combustible alternatives can accelerate declines in cigarette smoking, whereas opponents continue to emphasise concerns related to youth uptake, nicotine dependence, and long-term uncertainty. The debate reflects broader tensions between abstinence-focused tobacco control strategies and approaches centred on relative risk, consumer behaviour, and evidence-based harm reduction.

Criticism of global tobacco control policy is increasingly focusing on the way smoking continues to shape public health thinking around nicotine. Researchers and harm reduction advocates argue that many regulatory frameworks still approach all nicotine products through the historical lens of combustible cigarettes, despite major differences in toxicological risk. The discussion highlights concerns that outdated assumptions about nicotine may be influencing public perception, media narratives, and policy decisions surrounding reduced-risk alternatives. Questions are increasingly being raised over whether public health institutions are adapting quickly enough to scientific evidence and evolving patterns of nicotine use.

Belgium’s decision to ban vape flavours is intensifying debate over the role of flavours in smoking cessation and tobacco harm reduction. Supporters of the restrictions argue that flavour bans are necessary to reduce youth appeal and nicotine uptake, while critics warn that such measures may also make vaping less effective or attractive for adult smokers attempting to quit cigarettes. Researchers continue to debate whether flavour restrictions adequately balance youth prevention goals with evidence suggesting that non-tobacco flavours can play an important role in switching away from combustible tobacco. The policy change reflects wider international tensions surrounding nicotine regulation, risk communication, and evidence-based approaches to reducing smoking-related disease and mortality.

The UK’s new Tobacco and Vapes Act is intensifying debate over whether current tobacco control policies adequately support existing smokers attempting to quit. While the legislation aims to create a “smoke-free generation” by phasing out future tobacco sales, critics argue that restrictions on vape advertising, flavours, and alternative nicotine products may unintentionally reduce access to lower-risk options for adult smokers. Researchers and harm reduction advocates continue to warn that policies focused primarily on prohibition and youth prevention risk overlooking the role of non-combustible nicotine products in smoking cessation. The debate reflects broader tensions between public health prevention strategies, consumer behaviour, and evidence-based approaches to reducing smoking-related disease and mortality.

Stigma surrounding nicotine use and smoking continues to be recognised as an important barrier to smoking cessation and harm reduction. Researchers and public health commentators increasingly argue that shame-based messaging may discourage smokers from seeking support, switching to lower-risk alternatives, or engaging openly with healthcare systems. The discussion highlights growing concern that moralised narratives around nicotine can oversimplify addiction while reducing the effectiveness of public health communication. Questions remain over whether future tobacco control strategies can better balance prevention goals with approaches grounded in empathy, behavioural science, and evidence-based harm reduction.

Debates surrounding vaping policy are increasingly framed as a conflict between protecting youth and supporting tobacco harm reduction for adult smokers. Critics argue that presenting these objectives as mutually exclusive oversimplifies a far more complex public health challenge. Researchers and policy analysts continue to emphasise that reducing youth nicotine uptake and expanding access to lower-risk alternatives for smokers do not necessarily require opposing regulatory approaches. The discussion reflects broader tensions around risk communication, nicotine perception, and whether public health policy can simultaneously prioritize prevention, harm reduction, and evidence-based regulation.